P53 EXPRESSION AS A RISK FACTOR IN TYPE 1 ENDOMETRIAL CANCER | ||||
| ALEXMED ePosters | ||||
| Article 1, Volume 5, Issue 1, January 2023, Page 30-31 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2023.196367.1571 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mahmoud El-Saied Melies1; Ahmed Samy El-Agwany2; Rania Gaber Mohamed Aly3; Thacien Ndisebuye  2
| ||||
| 1Department of Obstetrics and Gynecology ,Faculty of Medicine, Alexandria University, Egypt | ||||
| 2Department of Obstetrics and Gynecology, ElShatby University Hospital, Faculty of Medicine, Alexandria University, Egypt | ||||
| 3Department of Pathology , Miri University Hospital, Faculty of Medicine, Alexandria University, Egypt | ||||
| Abstract | ||||
| Introduction: Tumor genesis has been thought to be significantly influenced by mutations of the tumor suppressor gene p53. In several types of cancer, clinically excessive p53 expression or the complete absence of p53 detection are predictive of TP53 mutations and have been linked to a poor prognosis. P53-abnormal proteins are one of the prognostic factors associated with a poor outcome in endometrial cancer. Type 1 endometrial carcinoma is the most frequent type of endometrial carcinoma and is generally associated with better clinical outcomes. Despite this, the incidence of recurrence is increasing. Few studies have explored the prevalence of p53 expression in this type of cancer in routine clinical practice. Immunohistochemistry for p53 is accurate and can help stratify those who could have aggressive molecular p53 mutants but with favourable clinicopathologic features. Aim of the Work: The aim of this study was to investigate the prevalence of P53 expression by immunohistochemistry among patients with type 1 endometrial cancer. | ||||
| Keywords | ||||
| P53 EXPRESSION; TYPE 1 ENDOMETRIAL CANCER; P53 null-type | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 70 |
||||
